Table 1 Patient characteristics.

Age at diagnosis, years – median (range)

53 (23–97)

54 (23–97)

51 (28–76)

0.172

Race^a

0.693

 White

386 (74.8%)

335 (74.3%)

51 (78.5%)

 African American

101 (19.6%)

89 (19.7%)

12 (18.5%)

 Asian

8 (1.6%)

8 (1.8%)

0 (0%)

 Other

20 (3.9%)

18 (4.0%)

2 (3.1%)

Ethnicity^b

0.537

 Non-Hispanic

497 (96.3%)

434 (96.2%)

63 (96.9%)

 Hispanic

14 (2.7%)

13 (2.9%)

1 (1.5%)

Menopausal status^c

0.127

 Premenopausal

214 (41.5%)

181 (40.1%)

33 (50.8%)

 Postmenopausal

295 (57.2%)

263 (58.3%)

32 (49.2%)

TNM stage

0.102

 Stage I

179 (34.7%)

150 (33.3%)

29 (44.6%)

 Stage II

263 (51.0%)

232 (51.4%)

31 (47.7%)

 Stage III

74 (14.3%)

69 (15.3%)

5 (7.7%)

T stage

0.256

 TX

3 (0.6%)

3 (0.7%)

0 (0.0%)

 T1

183 (35.7%)

153 (34.2%)

30 (46.2%)

 T2

263 (51.3%)

235 (52.5%)

28 (43.1%)

 T3

56 (10.9%)

49 (10.9%)

7 (10.8%)

 T4

11 (2.1%)

11 (2.5%)

0 (0.0%)

Nodal status

0.357

 Positive

117 (34.3%)

158 (35.0%)

19 (29.2%)

 Negative

339 (65.7%)

293 (65.0%)

46 (70.8%)

Histological grade

0.824

 I

2 (0.4%)

2 (0.4%)

0 (0.0%)

 II

86 (16.7%)

76 (16.9%)

10 (15.4%)

 III

428 (82.9%)

373 (82.7%)

55 (84.6%)

Germline BRCA1/2 deleterious mutation

0.530

 Yes

70 (13.6%)

64 (14.2%)

6 (9.2%)

 No

357 (69.2%)

309 (68.5%)

48 (73.8%)

 Unknown

89 (17.2%)

78 (17.3%)

11 (16.9%)

Chemotherapy received

0.307

 Neoadjuvant only

300 (58.1%)

269 (59.6%)

31 (47.7%)

 Adjuvant only

146 (28.3%)

122 (27.1%)

24 (36.9%)

 Neoadjuvant + adjuvant

58 (11.2%)

50 (11.1%)

8 (12.3%)

 None

12 (2.3%)

10 (2.2%)

2 (3.1%)

Neo/adjuvant chemotherapy regimen

N = 504

N = 441

N = 63

0.269

 Anthracycline-taxane-based

138 (27.4%)

123 (27.9%)

15 (23.8%)

 Anthracycline-taxane-based plus platinum

91 (18.1%)

81 (18.4%)

10 (15.9%)

 Taxane-based

61 (12.1%)

51 (11.6%)

10 (15.9%)

 Taxane-platinum-based

185 (36.7%)

164 (37.2%)

21 (33.3%)

 Other

29 (5.8%)

22 (5.0%)

7 (11.1%)

pCR (in patients with neoadjuvant chemotherapy)

N = 358

N = 319

N = 39

0.808

 Yes

177 (49.4%)

157 (49.2%)

20 (51.3%)

 No

181 (50.6%)

162 (50.8%)

19 (48.7%)

Surgery type^d

0.227

 Lumpectomy

205 (39.8%)

173 (38.4%)

32 (49.2%)

 Mastectomy

308 (59.8%)

275 (61.1%)

33 (50.8%)

 None

2 (0.4%)

2 (0.4%)

0 (0.0%)

Adjuvant radiation therapy^e

0.978

 Yes

304 (59.8%)

265 (59.8%)

39 (60.0%)

 No

204 (40.2%)

178 (40.2%)

26 (40.0%)

Adjuvant endocrine therapy

<0.001

 Yes

20 (3.9%)

7 (1.6%)

13 (20.0%)

 No

496 (96.1%)

444 (98.4%)

52 (80.0%)